TLS is a potentially serious complication of anticancer therapy. If left untreated, its progression may cause acute kidney failure, cardiac arrhythmias, seizures, loss of muscle control, and death.

With improvement in treatment options and supportive care, patients with MM are living longer. The majority of patients with MM are at risk for both osteolytic bone lesions and osteoporosis.

Nurse practitioners and other health care providers play a critical role in the recognition and management of cancer-related infections.

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin’s lymphoma (NHL) characterized by multiple recurrences requiring retreatment.

Castleman’s disease (CD) is a rare heterogeneous group of lymphoproliferative disorders that poses significant clinical challenges for oncologists and hematologists.

The introduction of biosimilar mAbs into the oncology treatment landscape has the potential to provide substantial cost savings without compromising treatment efficacy.

The heterogeneity of relapsed/refractory multiple myeloma (MM) and an increasing number of therapeutic options in this setting has resulted in a complex environment for treatment decisions. Multiple factors need to be considered when determining the next best therapy.

Because of the therapeutic advances and clinical research affecting the management of hematologic malignancies, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.  This peer interaction is an integral part in enhancing

The introduction of new treatment options in multiple myeloma (MM) has led to marked improvements in overall outcomes of patients.

Patients who do not respond to current therapies for myelodysplastic syndromes (MDS) have limited options. Advances in molecular testing suggest the potential for improved risk stratification and prognostication for patients with MDS.